GeLi Pharmaceutical-B (01672) received a voluntary commitment from the controlling shareholder to prohibit sales.

Intelligence Finance APP News, Gelsonpharma-B (01672) announced that, in order to express firm confidence in the long-term value and future prospects of the company, Dr. Wu Jinzi (founder of Gelsonpharma, chairman and CEO of the board of directors, and controlling shareholder of the company, Dr. Wu) and He Jingdao (executive director and controlling shareholder of the company, spouse of Dr. Wu, Mrs. Wu) have voluntarily committed not to sell (including but not limited to selling or pledging) any shares of the company directly or indirectly controlled by them or their respective entities before the following 3 clinical data readouts: (i) The top-line data of the US Phase I clinical study of ASC47 combined with semaglutide in obese subjects is expected to be obtained by the end of September 2025; (ii) The top-line data of the US 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects is expected to be obtained by December 2025; and (iii) The top-line data of the US Phase I single-dose escalation study of ASC50 in healthy subjects is expected to be obtained by December 2025.